Skip to main content
. 2022 Dec 28;28(3):e167–e170. doi: 10.1093/oncolo/oyac255

Table 2.

Safety and tolerability in patients with and without prior axitinib treatment.

AE Prior axitinib No prior axitinib
Treatment-related AE 84.5% 92.3%
Reduction due to AE 28.0% 29.7%
Interruption due to AE 53.5% 53.8%
Discontinuation due to AE 25.6% 19.8%

Abbreviation: AE, adverse event.